Monitoring Monoclonal Gammopathies
International Myeloma Working Group: 2009 Guidelines for Disease Monitoring 3
November 2009
In summary, the current guidelines for disease monitoring suggest: use serum and urine electrophoresis if there are measurable M-spikes, that is, >1g/dL in serum and >200 mg/24 hour in urine. And, if you use quantitive serum Ig for large M-spikes, remember that they should correlate with the M-spikes, but are not equivalent. In addition, if there is no measurable M-spike in serum or urine, use the serum free light chain quantitation if the free light chain ratio is abnormal and the monoclonal free light chain is >10 mg/dL.
2009 Guidelines |
Jump to section:
- Introduction
- Slide Images
- International Myeloma Working Group: Disease Monitoring
- Serum Protein Electrophoresis and Immunofixation Electrophoresis
- Serum and Urine Protein Electrophoresis and Immunofixation Electrophoresis
- Methods for Monitoring Monoclonal Gammopathies: 2005 IMWG
- Methods for Monitoring Monoclonal Gammopathies
- Small IgG kappa M-spike
- Large IgG kappa M-spike
- Relationship of Serum Agarose Electrophoresis M-spike and Ig Quantitation 1
- Disease Monitoring
- Monoclonal Gammopathies: Primary Systemic Amyloidosis
- Free Light Chain: Antibody Specificity
- FLC κ/λ Ratio: Disease Sensitivity 2
- Methods for Monitoring Monoclonal Gammopathies
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring 3
- Response Criteria for FLC 4,5
- Receiver Operator Curve (ROC): % FLC Reduction vs. Overall Hematologic Response 6
- International Myeloma Working Group: 2009 Guidelines for Disease Monitoring
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document